UK markets closed

Zevra Therapeutics, Inc. (ZVRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5100-0.1200 (-2.59%)
As of 01:57PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 193.78M
Enterprise value 185.35M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.23
Price/book (mrq)3.97
Enterprise value/revenue 6.69
Enterprise value/EBITDA -2.02

Trading information

Stock price history

Beta (5Y monthly) 1.87
52-week change 3-7.21%
S&P500 52-week change 327.84%
52-week high 37.2800
52-week low 33.8900
50-day moving average 35.0596
200-day moving average 35.2244

Share statistics

Avg vol (3-month) 3233.16k
Avg vol (10-day) 3186.36k
Shares outstanding 541.85M
Implied shares outstanding 642.49M
Float 836.1M
% held by insiders 18.39%
% held by institutions 133.83%
Shares short (30 Apr 2024) 42.65M
Short ratio (30 Apr 2024) 411.39
Short % of float (30 Apr 2024) 46.37%
Short % of shares outstanding (30 Apr 2024) 46.34%
Shares short (prior month 28 Mar 2024) 42.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 328 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:16
Last split date 328 Dec 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -178.47%
Operating margin (ttm)-598.13%

Management effectiveness

Return on assets (ttm)-27.75%
Return on equity (ttm)-82.27%

Income statement

Revenue (ttm)27.71M
Revenue per share (ttm)0.74
Quarterly revenue growth (yoy)7.80%
Gross profit (ttm)N/A
EBITDA -54.77M
Net income avi to common (ttm)-49.45M
Diluted EPS (ttm)-1.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)52.72M
Total cash per share (mrq)1.26
Total debt (mrq)44.29M
Total debt/equity (mrq)90.72%
Current ratio (mrq)2.10
Book value per share (mrq)1.17

Cash flow statement

Operating cash flow (ttm)-45.66M
Levered free cash flow (ttm)-14.47M